ID   NCI-H520
AC   CVCL_1566
SY   H520; H-520; NCI-HUT-520; NCIH520
DR   BTO; BTO:0003014
DR   CLO; CLO_0008093
DR   EFO; EFO_0003124
DR   AddexBio; C0016010/4915
DR   ArrayExpress; E-MTAB-38
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; HTB-182
DR   BCRC; 60124
DR   BioGRID_ORCS_Cell_line; 521
DR   BioSample; SAMN03471318
DR   BioSample; SAMN03472735
DR   BioSample; SAMN10987782
DR   cancercelllines; CVCL_1566
DR   CCRID; 5301HUM-KCB13023YJ
DR   Cell_Model_Passport; SIDM01130
DR   ChEMBL-Cells; CHEMBL3307864
DR   ChEMBL-Targets; CHEMBL614099
DR   CLS; 305063
DR   Cosmic; 687826
DR   Cosmic; 801591
DR   Cosmic; 876172
DR   Cosmic; 908443
DR   Cosmic; 917988
DR   Cosmic; 929974
DR   Cosmic; 932932
DR   Cosmic; 933580
DR   Cosmic; 945226
DR   Cosmic; 1028955
DR   Cosmic; 1146918
DR   Cosmic; 1219078
DR   Cosmic; 1239911
DR   Cosmic; 1741782
DR   Cosmic; 1802297
DR   Cosmic; 1995581
DR   Cosmic; 2060526
DR   Cosmic; 2125253
DR   Cosmic; 2560231
DR   Cosmic; 2648439
DR   Cosmic; 2664123
DR   Cosmic; 2668328
DR   Cosmic; 2696404
DR   Cosmic; 2772157
DR   Cosmic-CLP; 908443
DR   DepMap; ACH-000395
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001000978
DR   EGA; EGAS00001002554
DR   GDSC; 908443
DR   GEO; GSM63353
DR   GEO; GSM206494
DR   GEO; GSM274798
DR   GEO; GSM274831
DR   GEO; GSM276781
DR   GEO; GSM276782
DR   GEO; GSM434281
DR   GEO; GSM784258
DR   GEO; GSM794290
DR   GEO; GSM844653
DR   GEO; GSM844654
DR   GEO; GSM887433
DR   GEO; GSM888513
DR   GEO; GSM1374750
DR   GEO; GSM1670247
DR   IARC_TP53; 519
DR   IARC_TP53; 21409
DR   IGRhCellID; NCIH520
DR   KCB; KCB 2013023YJ
DR   LiGeA; CCLE_877
DR   LINCS_LDP; LCL-1591
DR   PharmacoDB; NCIH520_1117_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1566
DR   PubChem_Cell_line; CVCL_1566
DR   Ubigene; YC-C017
DR   Wikidata; Q54908073
RX   PubMed=1311061;
RX   PubMed=2388294;
RX   PubMed=3335022;
RX   PubMed=3940644;
RX   PubMed=8806092;
RX   PubMed=9649128;
RX   PubMed=10358721;
RX   PubMed=10536175;
RX   PubMed=11005564;
RX   PubMed=11030152;
RX   PubMed=11369051;
RX   PubMed=16187286;
RX   PubMed=18083107;
RX   PubMed=19472407;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=20557307;
RX   PubMed=22460905;
RX   PubMed=22961666;
RX   PubMed=24002593;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=26589293;
RX   PubMed=27397505;
RX   PubMed=27602502;
RX   PubMed=28196595;
RX   PubMed=29681454;
RX   PubMed=30894373;
RX   PubMed=30971826;
RX   PubMed=31068700;
RX   PubMed=31803961;
RX   PubMed=31978347;
RX   PubMed=35839778;
WW   https://tcpaportal.org/mclp/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: MD Anderson Cell Lines Project.
CC   Population: Caucasian.
CC   Doubling time: 61 hours (Note=In RPMI 1640 + 10% FBS), 25 hours (Note=In ACL-3), 32 hours (Note=In ACL-3 + BSA) (PubMed=3940644).
CC   HLA typing: A*11:01,11:01; B*15:18,15:18; C*07:04,07:04; DQB1*03:02,06:02; DRB1*11:04,11:04 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Pro383Ala (c.1147C>G); ClinVar=VCV001001330; Zygosity=Heterozygous (PubMed=27602502; Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Gly45Valfs*8 (c.134delG); Zygosity=Homozygous (Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Trp146Ter (c.438G>A); ClinVar=VCV000428890; Zygosity=Homozygous (PubMed=1311061; PubMed=10536175; PubMed=20557307; Cosmic-CLP; DepMap).
CC   Omics: Array-based CGH.
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0%; Native American=0%; East Asian, North=0.92%; East Asian, South=0%; South Asian=0%; European, North=63.58%; European, South=35.5% (PubMed=30894373).
CC   Derived from site: In situ; Lung; UBERON=UBERON_0002048.
ST   Source(s): AddexBio; ATCC; Cosmic-CLP; Genomics_Center_BCF_Technion; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 10
ST   D10S1248: 13
ST   D12S391: 21
ST   D13S317: 10,11
ST   D16S539: 8,13
ST   D18S51: 17
ST   D19S433: 13,14
ST   D1S1656: 14,16.3
ST   D21S11: 30
ST   D22S1045: 16
ST   D2S1338: 18,23
ST   D2S441: 10,11
ST   D3S1358: 16
ST   D5S818: 12 (PubMed=25877200)
ST   D5S818: 12,13 (AddexBio; ATCC; Cosmic-CLP; Genomics_Center_BCF_Technion)
ST   D7S820: 8,12
ST   D8S1179: 14,16,17
ST   FGA: 22
ST   Penta D: 13
ST   Penta E: 5,14
ST   TH01: 10
ST   TPOX: 8
ST   vWA: 18,19
DI   NCIt; C3493; Lung squamous cell carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 44
//
RX   PubMed=1311061;
RA   Mitsudomi T., Steinberg S.M., Nau M.M., Carbone D.P., D'Amico D.,
RA   Bodner S.M., Oie H.K., Linnoila R.I., Mulshine J.L., Minna J.D.,
RA   Gazdar A.F.;
RT   "p53 gene mutations in non-small-cell lung cancer cell lines and their
RT   correlation with the presence of ras mutations and clinical
RT   features.";
RL   Oncogene 7:171-180(1992).
//
RX   PubMed=2388294; DOI=10.1093/jnci/82.17.1420;
RA   McLemore T.L., Litterst C.L., Coudert B.P., Liu M.C., Hubbard W.C.,
RA   Adelberg S., Czerwinski M.J., McMahon N.A., Eggleston J.C., Boyd M.R.;
RT   "Metabolic activation of 4-ipomeanol in human lung, primary pulmonary
RT   carcinomas, and established human pulmonary carcinoma cell lines.";
RL   J. Natl. Cancer Inst. 82:1420-1426(1990).
//
RX   PubMed=3335022;
RA   Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J.,
RA   Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.;
RT   "Feasibility of drug screening with panels of human tumor cell lines
RT   using a microculture tetrazolium assay.";
RL   Cancer Res. 48:589-601(1988).
//
RX   PubMed=3940644;
RA   Brower M., Carney D.N., Oie H.K., Gazdar A.F., Minna J.D.;
RT   "Growth of cell lines and clinical specimens of human non-small cell
RT   lung cancer in a serum-free defined medium.";
RL   Cancer Res. 46:798-806(1986).
//
RX   PubMed=8806092; DOI=10.1002/jcb.240630505;
RA   Phelps R.M., Johnson B.E., Ihde D.C., Gazdar A.F., Carbone D.P.,
RA   McClintock P.R., Linnoila R.I., Matthews M.J., Bunn P.A. Jr.,
RA   Carney D.N., Minna J.D., Mulshine J.L.;
RT   "NCI-Navy Medical Oncology Branch cell line data base.";
RL   J. Cell. Biochem. 63 Suppl. 24:32-91(1996).
//
RX   PubMed=9649128; DOI=10.1038/bjc.1998.361;
RA   Yi S., Chen J.-R., Viallet J., Schwall R.H., Nakamura T., Tsao M.-S.;
RT   "Paracrine effects of hepatocyte growth factor/scatter factor on
RT   non-small-cell lung carcinoma cell lines.";
RL   Br. J. Cancer 77:2162-2170(1998).
//
RX   PubMed=10358721; DOI=10.18926/AMO/31626;
RA   Matsushita A., Tabata M., Ueoka H., Kiura K., Shibayama T., Aoe K.,
RA   Kohara H., Harada M.;
RT   "Establishment of a drug sensitivity panel using human lung cancer
RT   cell lines.";
RL   Acta Med. Okayama 53:67-75(1999).
//
RX   PubMed=10536175; DOI=10.3892/ijo.15.5.927;
RA   Fujita T., Kiyama M., Tomizawa Y., Kohno T., Yokota J.;
RT   "Comprehensive analysis of p53 gene mutation characteristics in lung
RT   carcinoma with special reference to histological subtypes.";
RL   Int. J. Oncol. 15:927-934(1999).
//
RX   PubMed=11005564; DOI=10.1038/sj.neo.7900094;
RA   Kohno T., Sato T., Takakura S., Takei K., Inoue K., Nishioka M.,
RA   Yokota J.;
RT   "Mutation and expression of the DCC gene in human lung cancer.";
RL   Neoplasia 2:300-305(2000).
//
RX   PubMed=11030152; DOI=10.1038/sj.onc.1203815;
RA   Modi S., Kubo A., Oie H.K., Coxon A.B., Rehmatulla A., Kaye F.J.;
RT   "Protein expression of the RB-related gene family and SV40 large T
RT   antigen in mesothelioma and lung cancer.";
RL   Oncogene 19:4632-4639(2000).
//
RX   PubMed=11369051; DOI=10.1016/S0165-4608(00)00363-0;
RA   Luk C., Tsao M.-S., Bayani J., Shepherd F.A., Squire J.A.;
RT   "Molecular cytogenetic analysis of non-small cell lung carcinoma by
RT   spectral karyotyping and comparative genomic hybridization.";
RL   Cancer Genet. Cytogenet. 125:87-99(2001).
//
RX   PubMed=16187286; DOI=10.1002/ijc.21491;
RA   Garnis C., Lockwood W.W., Vucic E., Ge Y., Girard L., Minna J.D.,
RA   Gazdar A.F., Lam S., MacAulay C., Lam W.L.;
RT   "High resolution analysis of non-small cell lung cancer cell lines by
RT   whole genome tiling path array CGH.";
RL   Int. J. Cancer 118:1556-1564(2006).
//
RX   PubMed=18083107; DOI=10.1016/j.cell.2007.11.025;
RA   Rikova K., Guo A.-L., Zeng Q.-F., Possemato A., Yu J., Haack H.,
RA   Nardone J., Lee K., Reeves C., Li Y., Hu Y.-R., Tan Z.-P., Stokes M.P.,
RA   Sullivan L., Mitchell J., Wetzel R., MacNeill J., Ren J.-M., Yuan J.,
RA   Bakalarski C.E., Villen J., Kornhauser J.M., Smith B., Li D.-Q.,
RA   Zhou X.-M., Gygi S.P., Gu T.-L., Polakiewicz R.D., Rush J., Comb M.J.;
RT   "Global survey of phosphotyrosine signaling identifies oncogenic
RT   kinases in lung cancer.";
RL   Cell 131:1190-1203(2007).
//
RX   PubMed=19472407; DOI=10.1002/humu.21028;
RA   Blanco R., Iwakawa R., Tang M.-Y., Kohno T., Angulo B., Pio R.,
RA   Montuenga L.M., Minna J.D., Yokota J., Sanchez-Cespedes M.;
RT   "A gene-alteration profile of human lung cancer cell lines.";
RL   Hum. Mutat. 30:1199-1206(2009).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=20557307; DOI=10.1111/j.1349-7006.2010.01622.x;
RA   Iwakawa R., Kohno T., Enari M., Kiyono T., Yokota J.;
RT   "Prevalence of human papillomavirus 16/18/33 infection and p53
RT   mutation in lung adenocarcinoma.";
RL   Cancer Sci. 101:1891-1896(2010).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=22961666; DOI=10.1158/2159-8290.CD-12-0112;
RA   Byers L.A., Wang J., Nilsson M.B., Fujimoto J., Saintigny P.,
RA   Yordy J., Giri U., Peyton M., Fan Y.-H., Diao L.-X., Masrorpour F.,
RA   Shen L., Liu W.-B., Duchemann B., Tumula P., Bhardwaj V., Welsh J.,
RA   Weber S., Glisson B.S., Kalhor N., Wistuba I.I., Girard L.,
RA   Lippman S.M., Mills G.B., Coombes K.R., Weinstein J.N., Minna J.D.,
RA   Heymach J.V.;
RT   "Proteomic profiling identifies dysregulated pathways in small cell
RT   lung cancer and novel therapeutic targets including PARP1.";
RL   Cancer Discov. 2:798-811(2012).
//
RX   PubMed=24002593; DOI=10.1038/bjc.2013.452;
RA   Wu D., Pang Y., Wilkerson M.D., Wang D., Hammerman P.S., Liu J.S.;
RT   "Gene-expression data integration to squamous cell lung cancer
RT   subtypes reveals drug sensitivity.";
RL   Br. J. Cancer 109:1599-1608(2013).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=27602502; DOI=10.18632/oncotarget.11845;
RA   Weber A.M., Drobnitzky N., Devery A.M., Bokobza S.M., Adams R.A.,
RA   Maughan T.S., Ryan A.J.;
RT   "Phenotypic consequences of somatic mutations in the
RT   ataxia-telangiectasia mutated gene in non-small cell lung cancer.";
RL   Oncotarget 7:60807-60822(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=29681454; DOI=10.1016/j.cell.2018.03.028;
RA   McMillan E.A., Ryu M.-J., Diep C.H., Mendiratta S., Clemenceau J.R.,
RA   Vaden R.M., Kim J.-H., Motoyaji T., Covington K.R., Peyton M.,
RA   Huffman K., Wu X.-F., Girard L., Sung Y., Chen P.-H., Mallipeddi P.L.,
RA   Lee J.Y., Hanson J., Voruganti S., Yu Y., Park S., Sudderth J.,
RA   DeSevo C., Muzny D.M., Doddapaneni H., Gazdar A.F., Gibbs R.A.,
RA   Hwang T.H., Heymach J.V., Wistuba I.I., Coombes K.R., Williams N.S.,
RA   Wheeler D.A., MacMillan J.B., DeBerardinis R.J., Roth M.G.,
RA   Posner B.A., Minna J.D., Kim H.S., White M.A.;
RT   "Chemistry-first approach for nomination of personalized treatment in
RT   lung cancer.";
RL   Cell 173:864-878.e29(2018).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31803961; DOI=10.1002/jcb.29564;
RA   Mulshine J.L., Ujhazy P., Antman M., Burgess C.M., Kuzmin I.A.,
RA   Bunn P.A. Jr., Johnson B.E., Roth J.A., Pass H.I., Ross S.M.,
RA   Aldige C.R., Wistuba I.I., Minna J.D.;
RT   "From clinical specimens to human cancer preclinical models -- a journey
RT   the NCI-cell line database-25 years later.";
RL   J. Cell. Biochem. 121:3986-3999(2020).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//